Enhanced dendritic cell-based immunotherapy using lowdose cyclophosphamide and CD25-targeted antibody for transplanted lewis lung carcinoma cells

Journal of Immunotherapy

Volumn 38, Issue 3, 2015, Pages 107-115

  Son, Cheol Hun ^a,b   Bae, Jae Ho ^b   Lee, Hong Rae ^a   Shin, Dong Yeok ^a   Yang, Kwangmo ^a   Park, You Soo ^a  

^a Dongnam Institute of Radiological and Medical Science   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

CD25 targeted antibody; cyclophosphamide (CTX); Dendritic cells (DCs); ionizing radiation (IR); regulatory T cell (Treg)

Indexed keywords

CD25 ANTIBODY; CELL ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DENDRITIC CELL BASED IMMUNOTHERAPY; IMMUNE RESPONSE; IMMUNOMODULATION; IONIZING RADIATION; IRRADIATION; LEWIS LUNG CARCINOMA CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CYTOTOXICITY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; RADIATION; RADIATION RESPONSE; SPLEEN; TH1 CELL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; PHENOTYPE; RADIATION; SPLEEN; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR MICROENVIRONMENT;

EID: 84925670394     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000068     Document Type: Article

References (40)

1. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci. 2003;987:180-187.
2. Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000;89:2646-2654.
3. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28:129-135.
4. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des. 2002;8:1765-1780.
5. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10:718-726.
6. Fazle Akbar SM, Abe M, Yoshida O, et al. Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes. Curr Med Chem. 2006;13:3113-3119.
7. Zou W. Regulatory T cells, tumour immunity and immuno-therapy. Nat Rev Immunol. 2006;6:295-307.
8. Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-812.
9. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest. 2002;110:289-294.
10. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6: 331-337.
11. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445:766-770.
12. Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118:3003-3012.
13. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol. 2006;16:106-114.
14. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007;2007:1-11.
15. Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4 +CD25 + T regulatory cells. J Immunol. 2006;176:3301-3305.
16. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59:3128-3133.
17. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
18. Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4 + CD25+Foxp3+ regulatory T cells by low-dose cyclo-phosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70:4850-4858.
19. Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33:369-383.
20. Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol. 2010;71: 70-82.
21. Matsushita N, Pilon-Thomas SA, Martin LM, et al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008;333: 167-179.
22. McCoy KD, Hermans IF, Fraser JH, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med. 1999;189:1157-1162.
23. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 2005;65:5958-5964.
24. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 2001;22: 141-148.
25. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer. 2001;94:825-833.
26. Hallahan DE, Spriggs DR, Beckett MA, et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA. 1989;86:10104-10107.
27. Hong JH, Chiang CS, Tsao CY, et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol. 1999;75: 1421-1427.
28. McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res. 2004;162:1-19.
29. Dasgupta A, Saxena R. Regulatory T cells: a review. Natl Med J India. 2012;25:341-351.
30. Sampson JH, Schmittling RJ, Archer GE, et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One. 2012;7:e31046.
31. Goebel J, Stevens E, Forrest K, et al. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol. 2000;8:153-159.
32. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1-12.
33. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
34. Ikezawa Y, Nakazawa M, Tamura C, et al. Cyclophosphamide decreases the number, percentage and the function of CD25 + CD4 + regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci. 2005;39:105-112.
35. Park YS, Bae JH, Son CH, et al. Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor. Immunol Invest. 2011;40:383-399.
36. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclo-phosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-648.
37. Salem ML, Kadima AN, El-Naggar SA, et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8 + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007;30: 40-53.
38. Liu P, Jaffar J, Hellstrom I, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010;33:53-59.
39. Nakahara T, Uchi H, Lesokhin AM, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010;115:4384-4392.
40. Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010;16:5067-5078.